NewcelX Ltd.
Last updated September 27, 2026
Organization details
- Legal name
- NewcelX Ltd.
- Former names
- NLS Pharmaceutics Ltd.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Switzerland
- Headquarters city
- Zurich
- Headquarters country
- Switzerland
- Fiscal year end
- December
- Ticker symbol
- NCEL
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001783036
Board of directors
-
Alexander Zwyer · DirectorSince 2026
-
Eran Israel Iohan · DirectorSince 2026
-
Liora Oren · DirectorSince 2026
-
Michel Revel · Director · CSO and DirectorSince 2026
-
Olivier Samuel · DirectorSince 2026
-
Ronen Twito · Director · Chairman and CEOSince 2026
-
Tamar Galili · DirectorSince 2026
Chief executives
Ronen Twito
· Chairman and CEO
Since March 2026
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $374,998
- 2 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 27, 2026 | Olivier Samuel Director | Open-market purchase | +81,818 | $2.75 | $225,000 |
| Apr 27, 2026 | Michel Revel Director, Officer (CSO and Director), 10% owner | Open-market purchase | +54,545 | $2.75 | $149,999 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.